Treatment of premenstrual dysphoria with selective serotonin re-uptake inhibitors: focus on safety.
Many women experience physical or mood symptoms associated with the menstrual cycle. For approximately 3 - 8% of women, the symptoms are severe enough to significantly affect social, domestic and occupational functioning. This cluster of primarily emotional and behavioural symptoms is now labelled premenstrual dysphoric disorder (PMDD). Women who meet criteria for PMDD do not usually respond to conservative interventions; selective serotonin re-uptake inhibitors (SSRIs) taken either daily or intermittently are considered to be an effective first-line therapy for this population. In this paper, the authors report on the efficacy and tolerability of SSRIs that are currently recognised as the treatment of choice for PMDD.
Macdougall
Mary
M
Women's Health Concerns Clinic, St Joseph's Healthcare, Fontbonne Building, 301 James Street S., Hamilton, Ontario L8P 3B6, Canada. mst@mcmaster.ca
Steiner
Meir
M
D001942:Breast Feeding; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004347:Drug Interactions; D005260:Female; D006801:Humans; D010349:Patient Compliance; D011247:Pregnancy; D011293:Premenstrual Syndrome / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology; D018570:Risk Assessment; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*
D017367:Selective Serotonin Reuptake Inhibitors